Neuron-specific enolase can be used as the sole guide to treat small-cell lung cancer patients in common clinical practice

Splinter, T. A. W.; Carney, D. N.; Teeling, M.; Peake, Michael; Kho, G. S.; Oosterom, R.; Cooper, Edward H.

doi:10.1007/bf00400971

Cited by 19 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Amongst them were eight immunohistochemical biomarkers, none of which could predict chemotherapy response and survival rate and there was only a weak correlation between marker level and treatment response [ 28 ]. Neuron specific enolase ( NSE ) was used for monitoring SCLC patients and found to be only useful in patients with an increased pre-treatment level [ 29 ]. The levels of lactate dehydrogenase and chromogranin A did not correlate with treatment response [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Quantification of Cell-Free mSHOX2 Plasma DNA for Therapy Monitoring in Advanced Stage Non-Small Cell (NSCLC) and Small-Cell Lung Cancer (SCLC) Patients

et al. 2015

View full text Add to dashboard Cite

PurposeMost patients suffering from advanced lung cancer die within a few months. To exploit new therapy regimens we need better methods for the assessment of a therapy response.Material and MethodsIn a pilot study we prospectively enrolled 36 patients with advanced NSCLC and SCLC (34 stage IV, 2 stage IIIB) of whom 34 received standard platinum-based chemo/radiotherapy and two were treated with a tyrosine kinase inhibitor. We measured the levels of extracellular methylated SHOX2 DNA (mSHOX2) in plasma before and during therapy until re-staging. The mSHOX2 analysis was blinded with respect to the clinical data making it an observational study.ResultsAccording to the re-staging of 31 first-line patients, 19 patients were classified as non-responders while 12 patients were in the responder group. We observed a tight correlation between radiological data and the change of plasma mSHOX2 level as the equivalent for a therapy response. A ROC analysis showed a high discriminatory power for both patient groups already one week after therapy start (AUC 0.844). Additionally, a Kaplan-Meier and Cox Proportional Hazards analyses revealed a strong relationship between survival and plasma mSHOX2 value p≤0.001 (hazard ratio 11.08) providing some evidence for mSHOX2 also being a predictive marker.ConclusionThe longitudinal measurement of extracellular plasma mSHOX2 DNA yields information about the response to cytotoxic treatment and allows an early assessment of treatment response for lung cancer patients. If confirmed in a larger study this would be a valuable tool for selecting and guiding a cytotoxic treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Quantification of Cell-Free mSHOX2 Plasma DNA for Therapy Monitoring in Advanced Stage Non-Small Cell (NSCLC) and Small-Cell Lung Cancer (SCLC) Patients

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Neuron-specific enolase (NSE) is one of the most widely used tumour markers in SCLC. It has been shown to be a clinically reliable tool to monitor the course of the disease (Cooper et al, 1985;Splinter et al, 1987a;Splinter et al, 1989), the doubling-time of NSE at relapse was highly significantly correlated with survival from time of relapse (Splinter et al, 1987b) and pretreatment-values were shown to have prognostic value by some (J0rgenson et al, 1988), but not by others (Van der Gaast et al, 1991). Moreover NSE is a good marker for neuronal differentiation and maturation (Schmechel et al, 1980).…”

Section: Discussionmentioning

confidence: 99%

Distinction of two different classes of small-cell lung cancer cell lines by enzymatically inactive neuron-specific enolase

Splinter

Verkoelen²,

Vlastuin³

et al. 1992

Br J Cancer

View full text Add to dashboard Cite

Summary Neuron specific enolase (NSE) is widely used as a neuro-endoctrine marker. However the presence of NSE in many non-neuroendocrine tissues has raised questions on the specificity of NSE. We have investigated NSE immunoreactivity (NSA-ag), y-enolase activity and total enolase activity in small cell lung cancer (SCLC) (Bepler et al., 1987;Carney et al., 1985;Gazdar et al., 1985;Bepler et al., 1989a;Broers et al., 1985;Moody et al., 1985;Broers et al., 1988 NSE is widely used as a neuroendocrine marker. NSEimmuno reactivity is not only seen in neurons, but also in neuroendocrine cells present in endocrine glands and in the diffuse neuroendocrine systems of the lung, intestine, thymus and skin. NSE has been demonstrated in tumours, thought to arise from the neuroendocrine cell system, such as SCLC, neuroblastoma, carcinoid, pancreatic islet cell tumours and medullary thyroid carcinoma (Schmechel et al., 1978;Tapia et al., 1981;Wick et al., 1983). NSE is also present in erythrocytes, lymphocytes and platelets (Marangos et al., 1980b;Hullin et al., 1980) and in malignant lymphomas, testicular cancer, hypernephroma and non-small cell lung cancer (Takashi et al., 1989;Ariyoshi et al., 1983;Kuzmits et al., 1987;Pinto et al., 1989;Oka et al., 1989;Niehans et al. 1988). Such observations question the correlation between NSE and the neuroendocrine cell system (Schmechel, 1985 SCLC-cell linesThe SCLC-cell lines were generously provided by the

show abstract

“…SCLC is a neuroendocrine tumor characterized by the expression of pan-neuroendocrine markers including neuron-specific enolase (NSE), creatine kinase BB and chromogranin, and specific hormones and their receptors including bombesin (GRP) and IGF-1 [5,13,25,31]. Many of these substances may be elevated in the serum and/or plasma of patients with SCLC at presentation and, particularly in the case of NSE, may be of value as tumor markers, the levels falling if the disease responds to chemotherapy and rising if the disease progresses or relapses [13,32,33].…”

Section: Indirect Effectsmentioning

confidence: 99%

Somatostatin, Its Receptors and Analogs, in Lung Cancer

et al. 2001

View full text Add to dashboard Cite

Despite developments in diagnosis and treatment, lung cancer is the commonest cause of cancer death in Europe and North America. Due to increasing cigarette consumption, the incidence of the disease and resultant mortality is rising dramatically in women. Novel approaches to the management of lung cancer are urgently required. Somatostatin is a tetradecapeptide first identified in the pituitary and subsequently throughout the body particularly in neuroendocrine cells of the pancreas and gastrointestinal tract and the nervous system. The peptide has numerous functions including inhibition of hormone release, immunomodulation and neurotransmission and is an endogenous inhibitor of cell proliferation and angiogenesis. Somatostatin and its analogs, including octreotide (SMS 201–995), somatuline (BIM 23014) and vapreotide (RC-160), act by binding to specific somatostatin receptors (SSTR) of which there are 5 principal subtypes, SSTR-1–5. Although elevated plasma somatostatin levels may be detected in 14–15% of patients, tumor cell expression appears rare. SSTR may be expressed by lung tumors, particularly small cell lung cancer and bronchial carcinoid disease. [¹¹¹In]pentetreotide scintigraphy may have a role to play in the localization and staging of lung cancers both before and following treatment, and in detecting relapsed disease. The potential role of radiolabelled somatostatin analogs as radiotherapeutic agents in the management of lung cancer is currently being explored. Somatostatin analog therapy results in significant growth inhibition of both SSTR-positive and SSTR-negative lung tumors in vivo. Recent work indicates that these agents may enhance the efficacy of chemotherapeutic agents in the treatment of solid tumors including lung cancer.

show abstract

Neuron-specific enolase can be used as the sole guide to treat small-cell lung cancer patients in common clinical practice

Cited by 19 publications

References 2 publications

Quantification of Cell-Free mSHOX2 Plasma DNA for Therapy Monitoring in Advanced Stage Non-Small Cell (NSCLC) and Small-Cell Lung Cancer (SCLC) Patients

Quantification of Cell-Free mSHOX2 Plasma DNA for Therapy Monitoring in Advanced Stage Non-Small Cell (NSCLC) and Small-Cell Lung Cancer (SCLC) Patients

Distinction of two different classes of small-cell lung cancer cell lines by enzymatically inactive neuron-specific enolase

Somatostatin, Its Receptors and Analogs, in Lung Cancer

Contact Info

Product

Resources

About